Latest Breaking News On - முதலீட்டாளர் தொடர்பு க்கு - Page 1 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights Medicenna Therapeutics Corp.February 12, 2021 GMT TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) Medicenna Therapeutics Corp. (“Medicenna” or “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. “Last quarter we achieved key regulatory milestones across our pipeline that position us for what we expect to be a catalyst rich calendar year,” said Dr. Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna. “The FDA’s acceptance of our precedent-setting registration trial design for MDNA55 in recurrent glioblastoma we believe has bolstered our pursuit

United kingdomUnited statesElizabeth williamsDavid reardonAmy mckee parexelMedicenna or companyGlioblastoma drug development summitDrug administrationHarvard medical schoolRegulatory agencyMedicenna therapeutics corpRecurrent glioblastoma programJohn sampson duke school of medicineSuperkine programFahar merchantChief executive officer